Moderna's new crown vaccine starts Phase 3 clinical! Nearly $1 billion in funding.

On July 27, Moderna announced that phase 3 of the mRNA vaccine (mRNA-1273) developed by the company for the new coronavirus had begun to administer to participantsThe Phase 3 study, known as the COVE (Corona Efficvirusacy) study, is conducted in collaboration with the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA)On the same day, Moderna announced an update of its contract with BARDA, which will provide up to $472 million in additional funding to support the phase 3 study of mRNA-1273Previously, BARDA committed $483 million to support large-scale production of mRNA-1273 and clinical development, with a small number of expected participants in the initial planned Phase 3 clinical trialWith Moderna's decision to conduct a larger Phase 3 clinical trial, the terms of the contract were revised and BARDA expanded its support for the late-stage clinical development of mRNA-1273, bringing the total funding to approximately $955 millionThis randomized double-blind, placebo-controlled Phase 3 COVE clinical trial (NCT04470427) is expected to enroll about 30,000 participants in the group, with a dose of 100 ?g as the dose of the vaccinationThe main endpoint of the trial will be the prevention of symptomatic COVID-19 disease; key secondary endpoints include prevention of severe COVID-19 disease (defined as requiring hospitalization) and prevention of COVID-19 caused by new coronavirus infectionmRNA-1273 is an mRNA vaccine for COVID-19, a stable form of COVID-19 encoded Spike (S) protein fusion, developed by researchers at the Moderna and NIAID Vaccine Research CenterThe first clinical trials were completed on February 7, 2020 and were analyzedThe first subject in Phase 1 of the study was given the drug on March 16On May 12, the FDA granted mRNA-1273 fast track eligibilityIn the second phase of the study, healthy adults aged 18-55 years (n-300) and those aged 55 and older (n-300) were fully groupedModerna also recently announced that mid-term analysis of mRNA-1273 1 studies has been published in the New England Journal of Medicine"We are pleased to start the 3rd PHASE of the COVE study," said DrStephane Bancel, Chief Executive Officer of ModernaWe thank our efforts, both inside and outside the company, to bring us to this important milestoneWe thank the participants and researchers of the COVE studyWe look forward to this trial proving that our vaccine has the potential to prevent COVID-19 so that it can defeat this pandemicModerna said it expects to supply about 500 million doses a year from 2021, possibly up to 1 billion dosesRelated: Moderna Announces Phase 3 COVE Study of mRNA Vaccinest COVID-19 (mRNA-1273) BeginsRetrieved 2020-07-27, from